Determination of carboplatin in human plasma using HybridSPE-precipitation along with liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 22, 2011, Pages 2162-2170

  Jiang, Hongliang ^a,b   Zhang, Yang ^b   Ida, Matt ^b   LaFayette, Amber ^b   Fast, Douglas M ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b 206 Carnegie Center   (United States)

Author keywords

Carboplatin; HybridSPE precipitation; LC MS MS; Matrix effects; Phospholipids removal; SCX

Indexed keywords

CARBOPLATIN; HYBRIDSPE-PRECIPITATION; LC-MS/MS; MATRIX EFFECTS; SCX;

ACETONITRILE; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; FORMIC ACID; ION CHROMATOGRAPHY; ION EXCHANGE; MASS SPECTROMETRY; OPTIMIZATION; PHOSPHOLIPIDS; PLASMA (HUMAN); PLASMAS;

QUALITY CONTROL;

ACETONITRILE; CARBOPLATIN; FORMIC ACID;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; ELUTION; FLOW RATE; HUMAN; HYBRID SOLID PHASE EXTRACTION PRECIPITATION; ION EXCHANGE CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MEASUREMENT ERROR; PRECIPITATION; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMICAL PRECIPITATION; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HUMANS; LEAST-SQUARES ANALYSIS; PHOSPHOLIPIDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TEMPERATURE;

EID: 79959912799     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.05.057     Document Type: Article

References (18)

1. Harland S.J., Newell D.R., Siddik Z.H., Chadwick R., Calvert A.H., Harrap K.R. Cancer Res. 1984, 44:1693.
2. Ruckdeschel J.D. Semin. Oncol. 1994, 21(5 Suppl. 12):114.
3. Reed E., Kohn K.W. Cancer Chemotherapy: Principles and Practices 1990, J.B. Lippincott Co., Philadelphia, PA, p. 465. B.A. Chabner, J.M. Collins (Eds.).
4. DesJardins C., Saxton P., Lu S.X., Li X., Rowbottom C., Wong Y.N. J. Chromatogr. B 2008, 875:373.
5. Pauer L.R., Olivares J., Cunningham C., Williams A., Grove W., Kraker A., Olson S., Nemunaitis J. Cancer Invest. 2004, 22:886.
6. Brouwers E.E.M., Tibben M.M., Rosing H., Hillebrand M.J.X., Joerger M., Schellens J.H.M., Beijnen J.H. J. Mass Spectrom. 2006, 41:1186.
7. Obasaju C.K., Johnson S.W., Rogatko A., Kilpatrick D., Brennan J.M., Hamilton T.C., Ozols R.F., O'Dwyer P.J., Gallo J.M. Clin. Cancer Res. 1996, 2:549.
8. Los G., Verdegaal E.M.E., Mutsaers P.H.A., McVie J.G. Cancer Chemother. Pharmacol. 1991, 28:159.
9. Burns R.B., Embree L. J. Chromatogr. B 2000, 744:367.
10. Guo P., Li S., Gallo J.M. J. Chromatogr. B 2003, 783:43.
11. Allsopp M.A., Sewell G.J., Rowland C.G. J. Pharm. Biomed. Anal. 1992, 10:375.
12. Elferink F., van der vijgh W.J., Pinedo H.M. Anal. Chem. 1986, 58:2293.
13. Burns R.B., Burton R.W., Albon S.P., Embree L. J. Pharm. Biomed. Anal. 1996, 14:367.
14. Falter R., Wilken R.-D. Sci. Total Environ. 1999, 225:167.
15. Hann S., Stefanka Z., Lenz K., Stingeder G. Anal. Bioanal. Chem. 2005, 381:405.
16. Zhang W., Seymour L., Chen E.X. J. Chromatogr. B 2008, 876:277.
17. Pucci V., Palma S.D., Alfieri A., Bonelli F., Monteagudo E. J. Pharm. Biomed. Anal. 2009, 50:867.
18. Zeng W., Xu Y., Constanzer M., Woolf E.J. J. Chromatogr. B 2010, 878:1817.